Since then, many randomized controlled clinical trials (DELIVER, EMPEROR-Preserved trials, DAPA-HF, EMPEROR-Reduced trial, DEFINE-HF, and SOLOIST-WHF trial) have been performed to evaluate the efficacy of SGLT-2 inhibitors in reducing major adverse outcomes in patients with established heart failure, regardless of the presence of T2DM [8, 9, 10, 11, 12, 13]. Here, SLC5A2 is linked to type 2 diabetes mellitus.